AKT1 and breast carcinoma: Consistent with our findings, Chen et al. have recently shown that PD166866 inhibited proliferation and triggered anoikis in FGFR1-amplified breast cancer cells and identified the suppression of the Akt/mTOR signaling pathway as the underlying mechanism [37].